Aug 15
Opportunity
Patients are experts in their condition and should inform clinical development. Patient / care partner input early on during the study design and protocol development can help improve patient experience in clinical trials, reduce patient burden, and increase recruitment, retention, and enrollment rates.
Considerations to Help Action the Opportunity
- Define internal sponsor processes to support patient / care partner engagement early in drug development, including budgetary requirements, contracts, IRB / ethics review, legal and data privacy issues, etc.
- Develop an engagement strategy early in the drug development process outlining the plan for identification of representative samples of patients, engagement method(s), timing of engagement(s), data utilization, sharing, assessment, etc.
- Understand investigator / clinical site perspective (in addition to patient / care partner input) of processes, investments and working practices
- Develop robust communication strategy to share information back to patients / care partners about how feedback influenced protocol design / other study elements and justification for when it was not used
- Understand patients / care partners input on the operational difficulties and the options for patients / care partners that can be included in trial design to overcome these
- Establish early partnerships among patients, sponsors, and investigators / clinical sites to build commitment for ongoing sharing of information
Value and Potential Benefits
- Improves patients’ clinical trial experience, reduces patient burden, and increases enrollment rates through patient-centric study design
- Establishes early connection between patients / participants and clinical development program, product / brand and company
- Improves the representation of diverse patient populations in clinical trials via tailored solutions and focused investments
Related Blog Posts
Redesigning Clinical Trials Using Artificial Intelligence
While tech evangelists often tout artificial intelligence (AI) as healthcare’s silver bullet, the reality in clinical trials is more complex. Adoption has been cautious, shaped as much by concerns around trust and governance as by technical hurdles. Still, beneath the surface, methodical innovation is gaining momentum. AI is beginning to reshape how trials are designed,…
How Pandemic-Era Ingenuity Fuels the Future of Clinical Trials
It’s hard to believe that just five years ago, the clinical research industry found itself scrambling to adapt overnight. The COVID-19 pandemic ground global health systems to a halt and forced us all to move faster and more collaboratively than ever before. Read the full article by Allison Cuff Shimooka from The Medicine Maker here.
Science is Moving—Clinical Trials Must Catch Up
Clinical research has never been more capable of reaching new frontiers. The science is here. The technology is here. But the approach to trial design and execution hasn’t kept pace. The clinical research ecosystem proceeds cautiously for good reasons—patient safety chief among them. But too often, we’re held back by fixed mindsets and outdated processes.…